Commonwealth Laboratories, a diagnostic laboratory headquartered in Salem, Mass., and Cedars-Sinai Medical Center have signed an exclusive license agreement for three patents owned by Cedars-Sinai that cover technology developed by Mark Pimentel, M.D., FRCPC, director of Cedars-Sinai’s gastrointestinal motility program and laboratory, and Henry C. Lin, M.D. These patents describe the use of hydrogen and methane breath testing in the diagnosis of irritable bowel syndrome (IBS) and other disorders caused by small intestinal bacterial overgrowth (SIBO).
SIBO is a condition in which abnormally large amounts of bacteria—100,000 bacteria per ml of fluid or more—are present in the small intestine. Prominent gastroenterologists have identified SIBO as a leading cause of IBS.
IBS is one of the most prevalent chronic medical conditions in the world today. It is estimated that 60 million Americans, and between 10% and 20% of the world population, suffer from the disorder. Hydrogen and methane breath testing is recognized by the American College of Gastroenterology as a non-invasive, patient-friendly method of diagnosing SIBO. Bacterial overgrowth can be identified quickly and efficiently by measuring for levels of hydrogen and methane in exhaled air.